Meena Thayu

Medicine · Health Sciences

30h-index3.6kcitations76works4.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(31), Inflammatory Bowel Disease(18), Microscopic Colitis(17), Lung Cancer Research Studies(12), Colorectal Cancer Treatments and Studies(9)

Publications76 total

Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed By Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind phase 3 Study (HOVON 181 AML / AMLSG 37-25)
Transplantation and Cellular Therapy·2026
Camelot-2: A phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A rearrangements or NPM1 mutations, Who Are Ineligible for Intensive Chemotherapy
Transplantation and Cellular Therapy·2026
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
Blood·2025· 1 cited
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Journal of Thoracic Oncology·2025· 12 citedOpen Access
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
Lung Cancer·2025· 4 citedOpen Access
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Journal of Thoracic Oncology·2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Journal of Thoracic Oncology·2025· 16 citedOpen Access
Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
Cancer Research·2024· 1 cited
Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.
Journal of Clinical Oncology·2024· 8 cited
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study
Cancer Treatment and Research Communications·2024· 1 citedOpen Access
OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
Journal of Thoracic Oncology·2023· 14 citedOpen Access
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer
Clinical Pharmacology & Therapeutics·2023· 7 citedOpen Access
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Nature Medicine·2023· 97 citedOpen Access
Amivantamab and lazertinib in treatment-naïve <i>EGFR-</i>mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
Journal of Clinical Oncology·2023· 7 cited
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
Lung Cancer·2023· 24 citedOpen Access
A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.
Journal of Clinical Oncology·2023
MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study
Annals of Oncology·2022· 1 citedOpen Access
Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
Journal of Clinical Oncology·2022· 51 cited
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
Journal of Clinical Oncology·2022· 60 cited
20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
Annals of Oncology·2022· 5 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Roland E. Knoblauch(22), Mary B. Leonard(19), Byoung Chul Cho(18), Robert N. Baldassano(15), Joshua C. Curtin(13), Babette S. Zemel(13), Alexander I. Spira(12), Catherine A. Shu(11), Joshua Bauml(11), Justine Shults(11), Rachel E. Sanborn(10), Amy Roshak(10), Eric B. Haura(8), Ji‐Youn Han(8), Joshua K. Sabari(8), Ki Hyeong Lee(8), John Xie(8), Lee A. Denson(8), Patricia Lorenzini(7), Jon M. Burnham(7)